Schrodinger, Inc. SDGR
We are transforming the way therapeutics and materials are discovered.
Our differentiated, physics-based computational platform enables discovery of high-quality, novel molecules for drug development and materials applications more rapidly and at a lower cost, compared to traditional methods. Our software platform is licensed by biopharmaceutical and industrial companies, academic institutions, and government laboratories around the world. We are applying our computational platform to advance a broad pipeline of drug discovery programs in collaboration with leading biopharmaceutical companies. In addition, we use our computational platform to discover novel molecules for our pipeline of proprietary drug discovery programs, which we are advancing through preclinical and clinical development.
Valuation FY2025 figures against the last close
Annual financial statements
Income statement
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $255.9M | $207.5M | $216.7M | $181.0M | $137.9M | $108.1M | $85.5M | — |
| Cost of revenue | $113.3M | $75.5M | $76.0M | $79.9M | $72.3M | $44.6M | $36.5M | — |
| Gross profit | $142.6M | $132.1M | $140.7M | $101.0M | $65.6M | $63.5M | $49.1M | — |
| R&D | $173.1M | $201.8M | $181.8M | $126.4M | $90.9M | $64.7M | $39.4M | — |
| SG&A | $95.4M | $99.7M | $99.1M | $90.8M | $64.0M | $41.9M | $27.0M | — |
| Total operating expenses | $309.5M | $341.4M | $318.1M | $247.8M | $177.1M | $124.4M | $87.8M | — |
| Operating income | -$166.9M | -$209.3M | -$177.4M | -$146.8M | -$111.4M | -$60.9M | -$38.7M | — |
| Pre-tax income | -$102.3M | -$185.7M | $42.9M | -$149.1M | -$100.8M | -$26.3M | -$26.0M | — |
| Income tax | $939.0K | $1.4M | $2.2M | $63.0K | $411.0K | $345.0K | $291.0K | — |
| Net income | -$103.3M | -$187.1M | $40.7M | -$149.2M | -$101.2M | -$24.5M | -$24.6M | — |
| EPS, basic | -1.41 | -2.57 | 0.57 | -2.10 | -1.42 | -0.41 | — | — |
| EPS, diluted | -1.41 | -2.57 | 0.54 | -2.10 | -1.42 | -0.41 | -4.09 | — |
| Shares, diluted (wtd. avg.) | $73.4M | $72.7M | $75.0M | $71.2M | $70.6M | $60.0M | — | — |
Balance sheet
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $230.5M | $147.3M | $161.1M | $95.7M | $123.3M | $202.8M | $26.5M | $77.7M |
| Short-term investments | $164.9M | $204.8M | $307.7M | $360.6M | $456.2M | $440.4M | $59.8M | — |
| Receivables | $83.0M | $235.7M | $66.0M | $56.0M | $31.7M | $31.4M | $18.7M | — |
| Total current assets | $519.3M | $635.0M | $567.8M | $534.0M | $625.1M | $683.0M | $118.5M | — |
| Property, plant and equipment | — | — | — | $14.2M | $10.0M | $5.1M | $6.3M | — |
| Goodwill | $4.8M | $4.8M | $4.8M | $4.8M | $0 | — | — | — |
| Other intangibles | — | — | $0 | $587.0K | $0 | — | — | — |
| Total assets | $726.2M | $823.2M | $803.0M | $688.6M | $756.5M | $746.3M | $155.3M | — |
| Accounts payable | $11.5M | $10.7M | $16.8M | $9.5M | $8.1M | $8.4M | $3.5M | — |
| Total current liabilities | $189.1M | $191.7M | $133.7M | $108.8M | $91.2M | $73.2M | $45.0M | — |
| Total liabilities | $362.1M | $401.8M | $254.4M | $240.7M | $199.4M | $122.2M | $57.0M | — |
| Retained earnings | -$628.8M | -$525.5M | -$338.4M | -$379.1M | -$230.0M | -$129.6M | -$105.1M | — |
| Total equity | $364.1M | $421.4M | $548.6M | $447.9M | $557.1M | $624.0M | -$93.3M | -$71.6M |
Cash flow
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $13.9M | -$157.4M | -$136.7M | -$119.7M | -$70.7M | $16.8M | -$26.1M | — |
| Depreciation and amortisation | $6.0M | $6.2M | $5.6M | $4.3M | $2.8M | $3.7M | $3.6M | — |
| Stock-based compensation | $43.0M | $49.9M | $47.8M | $39.6M | $26.5M | $10.5M | $2.2M | — |
| Capital expenditure | $1.4M | $7.3M | $13.4M | $8.0M | $7.2M | $2.5M | $1.8M | — |
| Investing cash flow | $57.9M | $148.8M | $193.0M | $90.0M | -$16.8M | -$381.7M | -$53.9M | — |
| Financing cash flow | $2.9M | $10.1M | $9.0M | $2.1M | $8.0M | $541.3M | $28.7M | — |
Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001490978-26-000026.
Others in SIC 2834
| Ticker | Company | Market cap | P/E | Revenue growth |
|---|---|---|---|---|
| AKTX | Akari Therapeutics Plc | $1.79T | — | — |
| LLY | ELI LILLY & Co | $1.08T | 50.1x | 44.7% |
| JNJ | JOHNSON & JOHNSON | $663.28B | 25.0x | 6.0% |
| ONC | BeOne Medicines Ltd. | $529.55B | 1,885.6x | 40.2% |
| ABBV | AbbVie Inc. | $453.19B | 108.7x | 8.6% |
| MRK | Merck & Co., Inc. | $370.89B | 20.6x | 1.3% |
| ABT | ABBOTT LABORATORIES | $188.69B | 29.1x | 5.7% |
| PFE | PFIZER INC | $162.16B | 20.9x | -1.6% |